Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_2
3
43%
Ph early_phase_1
1
14%
Ph phase_3
2
29%
Ph phase_1
1
14%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 32 (28.6%)

Trials by Status

withdrawn114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

NCT00551616
completedphase_3

Safety and Efficacy of CDB-2914 for Emergency Contraception

NCT00411684
completedphase_2

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
withdrawnearly_phase_1

CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women

NCT01493791
completedphase_2

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

NCT00791297
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00551616Phase 3

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Completed
NCT00411684Phase 3

Safety and Efficacy of CDB-2914 for Emergency Contraception

Completed
NCT00044876Phase 2

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

Completed
NCT01493791Early Phase 1

CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women

Withdrawn
NCT00791297Phase 2

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

Completed
NCT00041899Phase 1

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

Completed
NCT00271583Phase 2

Efficacy Trial of CDB 2914 for Emergency Contraception

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7